Yang et al., 2017 - Google Patents
Significance of phosphorylated epidermal growth factor receptor and its signal transducers in human soft tissue sarcomaYang et al., 2017
View HTML- Document ID
- 12274181104479807382
- Author
- Yang J
- Das Gupta R
- Goldstein D
- Crowe P
- Publication year
- Publication venue
- International Journal of Molecular Sciences
External Links
Snippet
Previous studies have shown that total epidermal growth factor receptor (EGFR) protein is highly expressed in soft tissue sarcoma (STS). We aimed to investigate the significance of phosphorylated-EGFR (pEGFR) and its activated-downstream signal transducers in STS …
- 206010039491 Sarcoma 0 title abstract description 91
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/01—Social networking
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q10/00—Administration; Management
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Birnbaum et al. | Head and body/tail pancreatic carcinomas are not the same tumors | |
| Tomasini et al. | EGFR and KRAS mutations predict the incidence and outcome of brain metastases in non-small cell lung cancer | |
| Passaro et al. | Genomic characterization of concurrent alterations in Non-Small Cell Lung Cancer (NSCLC) harboring actionable mutations | |
| Castello et al. | Circulating tumor cells and metabolic parameters in NSCLC patients treated with checkpoint inhibitors | |
| Donizy et al. | Up-regulation of PARP1 expression significantly correlated with poor survival in mucosal melanomas | |
| Wucherpfennig et al. | Evaluation of therapeutic targets in histological subtypes of bladder cancer | |
| Iannantuono et al. | Activity of alk inhibitors in renal cancer with alk alterations: A systematic review | |
| Ruggeri et al. | HER2 analysis in sporadic thyroid cancer of follicular cell origin | |
| Fiala et al. | Outcomes according to MSKCC risk score with focus on the intermediate-risk group in metastatic renal cell carcinoma patients treated with first-line sunitinib: a retrospective analysis of 2390 patients | |
| Yang et al. | Significance of phosphorylated epidermal growth factor receptor and its signal transducers in human soft tissue sarcoma | |
| Cimadamore et al. | Prostate cancer in 2021: novelties in prognostic and therapeutic biomarker evaluation | |
| Georgescu | Multi-platform classification of IDH-wild-type glioblastoma based on ERK/MAPK pathway: Diagnostic, prognostic and therapeutic implications | |
| Tang et al. | Clinical applications of cancer-associated cells present in the blood of cancer patients | |
| Kumaki et al. | Comprehensive genomic profiling of circulating cell-free DNA distinguishes focal MET amplification from aneuploidy in diverse advanced cancers | |
| Wang et al. | Co-expression with membrane CMTM6/4 on tumor epithelium enhances the prediction value of PD-L1 on anti-PD-1/L1 therapeutic efficacy in gastric adenocarcinoma | |
| Winter et al. | Alpha smooth muscle actin (αSMA) immunohistochemistry use in the differentiation of pancreatic cancer from chronic pancreatitis | |
| Di Liello et al. | Master protocols for precision medicine in oncology: overcoming methodology of randomized clinical trials | |
| Silva et al. | Baseline and kinetic circulating tumor cell counts are prognostic factors in a prospective study of metastatic colorectal cancer | |
| Braun et al. | Hormonal receptor status determines prognostic significance of FGFR2 in invasive breast carcinoma | |
| Jünger et al. | Timing of development of symptomatic brain metastases from non-small cell lung cancer: impact on symptoms, treatment, and survival in the era of molecular treatments | |
| Salati et al. | Clinical significance of molecular subtypes in western advanced gastric cancer: A real-world multicenter experience | |
| Mizoguchi et al. | Granzyme B expression in the tumor microenvironment as a prognostic biomarker for patients with triple-negative breast cancer | |
| Stella et al. | The q-lamp method represents a valid and rapid alternative for the detection of the bcr-abl1 rearrangement in philadelphia-positive leukemias | |
| Chang et al. | Nectin-4 as a Predictive Marker for Poor Prognosis of Endometrial Cancer with Mismatch Repair Impairment | |
| de Godoy Fernandes et al. | Morphological and molecular characterization of proliferative inflammatory atrophy in canine prostatic samples |